Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care.
In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics.
We cover:
- How liquid biopsy works and why cell-free DNA became such a powerful tool
- The path from late-stage applications to large-scale early detection
- What Medicare coverage of blood-based colorectal cancer screening signals for adoption
- The operational and regulatory hurdles that shape diagnostics businesses
- Lessons from Helmy’s entrepreneurial path across sequencing, diagnostics, and company-building
—
About our guest:
Helmy Eltoukhy is the chairman and co-CEO of Guardant Health, a leading precision oncology company he co-founded in 2012. He is also an active investor and is involved in over 30 startup companies across the technology and healthcare sectors. In December 2024, Eltoukhy expanded his ventures into sports ownership by co-leading the acquisition of Sheffield United Football Club through COH Sports of which he is currently co-chairman.
Last year, he was named by TIME100 Health as one of the most influential people in global health. He was also on Time Magazine’s inaugural list of the 50 Most Influential People in Health Care and has been recognized by Fortune (40 under 40), the World Economic Forum (Technology Pioneer), and on the list of the Top 50 Healthcare CEOs in 2021.
Beyond his entrepreneurial endeavors, Eltoukhy is deeply committed to various philanthropic efforts and serves on the boards of the Prostate Cancer Foundation, the SETI Institute (Search for Extraterrestrial Intelligence), and the UCSF Cancer Leadership Council. Prior to founding Guardant Health, Eltoukhy co-founded Avantome in 2007 to commercialize semiconductor sequencing, which was later acquired by Illumina. Eltoukhy is a named inventor on over 100 patents and holds PhD, MS, and BS degrees in electrical engineering from Stanford University.
—
Learn more about the Rock Health CEO Summit at the New York Stock Exchange on March 27th.
—
📍 Connect with us:
Heart of Healthcare website
LinkedIn
Instagram
Youtube
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
